Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 2/20 | 0.61 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.44 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.44 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8178136 | 0.89 | GCGR (0.64) | GCGRSLC10A2GRM6PRKCZGAA | |
| SCHEMBL9737768 | 0.89 | GCGR (0.64) | GCGRSLC10A2GAAPOLBMAPT | |
| SCHEMBL13482768 | 0.89 | GCGR (0.64) | GCGRSLC10A2GRM6PRKCZGAA | |
| SCHEMBL2648212 | 0.87 | GCGR (0.62) | GCGRSLC10A2GRM6PRKCZGAA | |
| SCHEMBL9152067 | 0.87 | GCGR (0.61) | GCGRSLC10A2GRM6PRKCZGAA | |
| SCHEMBL14189850 | 0.85 | GCGR (0.64) | GCGRSLC10A2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5102017 | 0.84 | GCGR (0.49) | GCGRSLC10A2GRM6PRKCZGAA | |
| SCHEMBL5098445 | 0.84 | GCGR (0.63) | GCGRSLC10A2MAPTMEN1KMT2A | |
| SCHEMBL6565362 | 0.83 | GCGR (0.79) | GCGRRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL5094936 | 0.83 | GCGR (0.54) | GCGRSLC10A2GRM6PRKCZMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7420059-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420059-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| EP-1684754-A1 | HMG-COA REDUCTASE INHIBITORS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050171140-A1 | Prevent cholesterol biosynthesis; moderating blood serum lipid ; antidiabetic agents; obesity; hypotensive agents; osteoporosis; Alzheimer's disease; cardiovascular disorders; hormone replacement therapy | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| WO-2005051386-A1 | HMG-COA REDUCTASE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0468258-B1 | Substituted pyrido-oxazines | BAYER AG (DE) | 1995-11-02 | — | — | EP | disclosed |
| US-5145857-A | HMG-COA REDUCTASE-INHIBITING SUBSTITUTED AMINO-PYRIDINES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| US-5137881-A | Anticholesterol, antilipemic agents | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| US-5120782-A | Treatment of hyperlipoproteinaemia, lipoproteinaemia and arteriosclerosis | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-09 | — | — | US | disclosed |
| EP-0468258-A1 | Substituted pyrido-oxazines | BAYER AG (DE) | 1992-01-29 | — | — | EP | disclosed |
| EP-0465970-A1 | Substituted pyrrolo-pyridines | BAYER AG (DE) | 1992-01-15 | — | — | EP | disclosed |
| EP-0416383-A2 | Substituted aminopyridines | BAYER AG (DE) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249583-A1 | HMG-CoA reductase inhibitors | HMGCR, LDLR, PCSK9 | GCGR 919/4885SLC10A2 1700/4885GRM6 2251/4885 |
| US-20050171140-A1 | Prevent cholesterol biosynthesis; moderating blood serum lipid ; antidiabetic agents; obesity; hypotensive agents; osteoporosis; Alzheimer's disease; cardiovascular disorders; hormone replacement therapy | HMGCR, LDLR, APOB | GCGR 124/4885SLC10A2 2144/4885GRM6 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.